fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approval of expanded approval for expanded Exparel label to include two additional nerve block indications – Pacira Biosciences

Written by | 23 Nov 2023

Pacira BioSciences, Inc. announced that the FDA has approved its supplemental new drug application (sNDA) to expand the Exparel (bupivacaine liposome injectable suspension) label to include administration in… read more.

Boston Scientific closes acquisition of Relievant Medsystems, Inc. and with it Intracept Intraosseous Nerve Ablation System

Written by | 22 Nov 2023

Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only FDA -cleared Intracept Intraosseous Nerve Ablation System, a therapy… read more.

FDA approval for DefenCath (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections – CorMedix

Written by | 21 Nov 2023

CorMedix Inc. announced that the FDA has approved DefenCath (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited… read more.

Health Canada approves Hemgenix (etranacogene dezaparvovec) for treating adults with hemophilia B who rely on routine prophylactic therapies to prevent or reduce bleeding episodes – CSL Behring

Written by | 20 Nov 2023

Health Canada has approved the gene therapy Hemgenix (etranacogene dezaparvovec) for treating adults with hemophilia B who rely on routine prophylactic therapies to prevent or reduce bleeding episodes…. read more.

CHMP recommends subcutaneous injection of Tecentriq for multiple cancer types – Roche

Written by | 19 Nov 2023

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin). Tecentriq (atezolizumab)…. read more.

FDA approval of Voqenza (vonoprazan) tablets for the treatment of erosive GERD and relief of heartburn associated with erosive GERD in adults – Phathom Pharma

Written by | 18 Nov 2023

Phathom Pharmaceuticals, Inc. announced the FDA has approved Voqenza (vonoprazan) tablets 10 mg and 20 mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults… read more.

CHMP positive for Talzenna + Xtandi (talazoparib + enzalutamide) to treatmetastatic castration-resistant prostate cancer – Pfizer

Written by | 17 Nov 2023

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Talzenna…. read more.

CHMP positive for Mounjaro (tirzepatide) for the treatment of obesity – Eli Lilly

Written by | 16 Nov 2023

Eli Lilly’s Mounjaro is recommended for use in Europe for the treatment of obesity. The recommendation comes the same week the drug was approved for obesity treatment in… read more.

Submission of phase III study data on pulmonary tuberculosis to the EMA and FDA for Sirturo (bedaquiline) – Janssen Pharma

Written by | 15 Nov 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for the Company’s medicine… read more.

CHMP positive for Omjjara (momelotinib) to treat myelofibrosis – GSK

Written by | 14 Nov 2023

On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.

National Medical Products Administration has approved for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment – Viiv HealthCare

Written by | 13 Nov 2023

GSK plc has announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders announced that the National Medical Products… read more.

New clinical data on Rayaldee (ER calcifediol) presented at Kidney Week 2023 – OPKO Health Inc

Written by | 12 Nov 2023

OPKO Health, Inc. presented late-breaking clinical data on Rayaldee extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia. These data, presented in a… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.